The requirements of nucleic acid test for COVID-19 during public health emergency: Current regulatory in Taiwan, Singapore, and the United States
- PMID: 36343271
- DOI: 10.1097/JCMA.0000000000000804
The requirements of nucleic acid test for COVID-19 during public health emergency: Current regulatory in Taiwan, Singapore, and the United States
Abstract
In mid-2022, the COVID-19 cases have reached close to 562 million, but its overall infection rate is hard to confirm. Even with effective vaccines, break-through infections with new variants occur, and safe and reliable testing still plays a critical role in isolation of infected individuals and in control of an outbreak of a COVID-19 pandemic. In response to this urgent need, the diagnostic tests for COVID-19 are rapidly evolving and improving these days. The health authorities of many countries issued requirements for detecting SARS-CoV-2 diagnosis tests during the pandemic and have timely access to these tests to ensure safety and effectiveness. In this study, we compared the requirements of EUA in Taiwan, Singapore, and the United States. For the performance evaluations of nucleic acid extraction, inclusivity, limit of detection (LoD), cross-reactivity, interference, cutoff, and stability, the requirements are similar in the three countries. The use of natural clinical specimens is needed for clinical evaluation in Taiwan and the United States. However, carry-over and cross-contamination studies can be exempted in Taiwan and the United States but are required in Singapore. This review outlines requirements and insight to guide the test developers on the development of IVDs. Considering the rapidly evolving viruses and severe pandemic of COVID-19, timely and accurate diagnostic testing is imperative to the management of diseases. As noted above, the performance requirements for SARS-CoV-2 nucleic acid tests are similar between Taiwan, Singapore and the United States. The differences are mainly in two points: the recommended microorganisms for cross-reactivity study, and the specimen requirement for clinical evaluation. This study provides an overview of current requirements of SARS-CoV-2 nucleic acid tests in Taiwan, Singapore, and the United States.
Copyright © 2022, the Chinese Medical Association.
Conflict of interest statement
Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.
Similar articles
-
Current Status of Diagnostic Testing for SARS-CoV-2 Infection and Future Developments: A Review.Med Sci Monit. 2020 Dec 17;26:e928552. doi: 10.12659/MSM.928552. Med Sci Monit. 2020. PMID: 33332288 Free PMC article. Review.
-
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.Trials. 2021 Jan 8;22(1):39. doi: 10.1186/s13063-020-04982-z. Trials. 2021. PMID: 33419461 Free PMC article.
-
Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.Microbiol Spectr. 2022 Feb 23;10(1):e0251321. doi: 10.1128/spectrum.02513-21. Epub 2022 Feb 23. Microbiol Spectr. 2022. PMID: 35196812 Free PMC article.
-
The National Laboratory Response to the COVID-19 Pandemic in Taiwan.Health Secur. 2022 Sep-Oct;20(5):368-375. doi: 10.1089/hs.2022.0024. Epub 2022 Sep 14. Health Secur. 2022. PMID: 36108302
-
SARS-CoV-2 and Variant Diagnostic Testing Approaches in the United States.Viruses. 2021 Dec 13;13(12):2492. doi: 10.3390/v13122492. Viruses. 2021. PMID: 34960762 Free PMC article. Review.
References
-
- Mohammadi M, Meskini M, do Nascimento Pinto AL. 2019 Novel coronavirus (COVID-19) overview. Z Gesundh Wiss. 2022;30:167–75.
-
- Yuan X, Yang C, He Q, Chen J, Yu D, Li J, et al. Current and perspective diagnostic techniques for COVID-19. ACS Infect Dis. 2020;6:1998–2016.
-
- Drexler JF, Gloza-Rausch F, Glende J, Corman VM, Muth D, Goettsche M, et al. Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J Virol. 2010;84:11336–49.
-
- Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418–23.
-
- Taiwan Centers for Disease Control, Prevention and Control of COVID-19 in Taiwan, 2021-1-5. Available at: https://www.cdc.gov.tw/En/Category/Page/0vq8rsAob_9HCi5GQ5jH1Q . Accessed 5 January, 2021.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous